tiprankstipranks
Blurbs

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Amgen (AMGN), Bio-Rad Laboratories (BIO) and Edwards Lifesciences (EW)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Amgen (AMGNResearch Report), Bio-Rad Laboratories (BIOResearch Report) and Edwards Lifesciences (EWResearch Report).

Amgen (AMGN)

In a report released yesterday, Jay Olson from Oppenheimer maintained a Buy rating on Amgen, with a price target of $294.00. The company’s shares closed last Wednesday at $246.41.

According to TipRanks.com, Olson is a 4-star analyst with an average return of 4.9% and a 39.4% success rate. Olson covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals, Crispr Therapeutics AG, and Intellia Therapeutics.

Amgen has an analyst consensus of Hold, with a price target consensus of $260.73, a 4.6% upside from current levels. In a report issued on January 19, Piper Sandler also maintained a Buy rating on the stock with a $293.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

Bio-Rad Laboratories (BIO)

In a report issued on January 30, Conor McNamara from RBC Capital maintained a Buy rating on Bio-Rad Laboratories, with a price target of $571.00. The company’s shares closed last Wednesday at $473.42.

According to TipRanks.com, McNamara is a 2-star analyst with an average return of 4.2% and a 66.7% success rate. McNamara covers the Healthcare sector, focusing on stocks such as Maravai Lifesciences Holdings, Thermo Fisher, and QuidelOrtho.

Currently, the analyst consensus on Bio-Rad Laboratories is a Moderate Buy with an average price target of $565.00.

Edwards Lifesciences (EW)

In a report released yesterday, William Plovanic from Canaccord Genuity maintained a Hold rating on Edwards Lifesciences, with a price target of $76.00. The company’s shares closed last Wednesday at $81.48.

According to TipRanks.com, Plovanic is a 3-star analyst with an average return of 2.8% and a 48.4% success rate. Plovanic covers the Healthcare sector, focusing on stocks such as Merit Medical Systems, TransMedics Group, and Staar Surgical.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Edwards Lifesciences with a $84.18 average price target, a 6.4% upside from current levels. In a report issued on January 30, Piper Sandler also downgraded the stock to Hold with a $80.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on AMGN:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles